1027. At-Home vs. In-Clinic Receipt of Cabotegravir and Rilpivirine Long-Acting: An Implementation Science Trial

BACKGROUND: Cabotegravir plus rilpivirine long acting (CAB + RPV LA) is administered as an intramuscular injection every 1 or 2 months for treatment of HIV-1 infection. The need for frequent travel to a clinic could impair treatment access. We hypothesized that receiving treatment at-home would be a...

Descripción completa

Detalles Bibliográficos
Autores principales: Williams, Jamila K, Young, Christina, Hanson, Rochelle F, Moreland-Johnson, Angela, Adekunle, Ruth O, Kirk, Stephanie, Meissner, Eric G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678687/
http://dx.doi.org/10.1093/ofid/ofad500.058

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678687/
http://dx.doi.org/10.1093/ofid/ofad500.058

Ejemplares similares